Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

08 sept. 2025 11h02 HE | Source: Research and Markets

Interferon Market by Indication, Interferon Type, Administration Route, End User, Product Type, Dosage Form and Region - Shares and Industry Forecast 2025-2030

Dublin, Sept. 08, 2025 (GLOBE NEWSWIRE) -- The "Interferon Market Forecast 2025-2030" has been added to ResearchAndMarkets.com's offering. The interferon market is entering a period of meaningful...
02 sept. 2025 19h30 HE | Source: Biogen Inc.

Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer’s Disease Under Fast Track Status

TOKYO and CAMBRIDGE, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge,...
02 sept. 2025 07h00 HE | Source: Biogen Inc.

Biogen and Stoke Therapeutics Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome

– Durable reductions in seizures and continuing improvements in cognition and behavior through 3 years in patients who continued to receive zorevunersen in the open-label extension studies – –...
29 août 2025 17h00 HE | Source: Biogen Inc.

FDA Approves LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease

LEQEMBI IQLIK is the first and only anti-amyloid treatment to offer an at-home injection to help patients and care partners continue to treat this progressive, relentless disease after initial...
25 août 2025 07h00 HE | Source: Biogen Inc.

Biogen and Stoke Therapeutics Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress

– 3-year data from open-label extension (OLE) studies demonstrate the potential for disease modification with durable seizure reductions and improvements in cognition and behavior on top of standard...
25 août 2025 03h00 HE | Source: Biogen Inc.

Austria and Germany to become the first markets in the European Union (EU) to launch LEQEMBI® (lecanemab)

TOKYO and CAMBRIDGE, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge,...
21 août 2025 12h30 HE | Source: Custom Market Insights

[Latest] Global Biologics and Biosimilars Market Size/Share Worth USD 1,320.19 Billion by 2034 at a 10.42% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

Austin, TX, USA, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Biologics and Biosimilars Market Size, Trends and Insights By Product Type...
21 août 2025 09h30 HE | Source: SNS Insider pvt ltd

Dementia Treatment Market Size to Surpass USD 33.54 Billion by 2032, Fueled by Breakthrough Therapies and Growing Patient Awareness – SNS Insider

Austin, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Dementia Treatment Market Size & Growth Outlook According to SNS Insider, the global Dementia Treatment Market was valued at USD 17.06 billion in 2023...
21 août 2025 09h00 HE | Source: SNS Insider pvt ltd

Ankylosing Spondylitis Market Size to Hit USD 11.15 Billion by 2032, Driven by Rising Biologic Therapies and Expanding Precision Medicine Landscape – SNS Insider

Austin, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Ankylosing Spondylitis Market Size & Growth Analysis According to SNS Insider, the Ankylosing Spondylitis Market was valued at USD 5.77 billion in 2023...
18 août 2025 04h12 HE | Source: Research and Markets

Dementia and Movement Disorder Treatment Market Outlook Report and Company Analysis 2025-2029

Dublin, Aug. 18, 2025 (GLOBE NEWSWIRE) -- The "Dementia and Movement Disorder Treatment Market 2025-2029" has been added to ResearchAndMarkets.com's offering. The dementia and movement disorder...

Page précédente

Page suivante